Elimination of hypoglycemia from the lives of people affected by diabetes

Diabetes

Volumn 60, Issue 1, 2011, Pages 24-27

  Cryer, Philip E ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALANINE; CAFFEINE; DIAZOXIDE; FLUOXETINE; GLUCAGON; GLUCOSE; INSULIN; MODAFINIL; NALOXONE; PHENTOLAMINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SULFONYLUREA; TERBUTALINE;

DIABETES MELLITUS; DIABETIC PATIENT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIGH RISK PATIENT; HORMONE RESPONSE; HUMAN; HYPOGLYCEMIA; IATROGENIC DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NOTE; PRIORITY JOURNAL;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HOMEOSTASIS; HUMANS; HYPERINSULINISM; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IATROGENIC DISEASE; INSULIN;

EID: 78751517198     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-1359     Document Type: Note

References (41)

1. Cryer PE. Hypoglycemia in Diabetes. Pathophysiology, Prevalence and Prevention. American Diabetes Association, Alexandria, VA, 2009
2. Cooperberg BA, Cryer PE. β-cell-mediated signaling predominates over direct α-cell signaling in the regulation of glucagon secretion in humans. Diabetes Care 2009;32:2275-2280
3. Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes 2010;59:2936-2940
4. Paranjape SA, Chan O, Zhu W, Horblitt AM, McNay EC, Cresswell JA, Bogan JS, McCrimmon RJ, Sherwin RS. Influence of insulin in the ventromedial hypothalamus on pancreatic glucagon secretion in vivo. Diabetes 2010;59:1521-1527
5. Fanelli CG, Epifano L, Rambotti AM, Pampanelli S, Di Vincenzo A, Modarelli F, Lepore M, Annibale B, Ciofetta M, Bottini P. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993;42:1683-1689
6. Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E. Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM. Diabetologia 1994;37:1265-1276
7. Cranston I, Lomas J, Maran A, Macdonald I, Amiel SA. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994;344:283-287
8. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994;43:1426-1434
9. Sherwin RS. Bringing light to the dark side of insulin: a journey across the blood-brain barrier. Diabetes 2008;57:2259-2268
10. Teves D, Videen TO, Cryer PE, Powers WJ. Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia. Proc Natl Acad Sci U S A 2004;101:6217-6221
11. Dunn JT, Cranston I, Marsden PK, Amiel SA, Reed LJ. Attenuation of amydgala and frontal cortical responses to low blood glucose concentration in asymptomatic hypoglycemia in type 1 diabetes: a new player in hypoglycemia unawareness? Diabetes 2007;56:2766-2773
12. Arbelaez AM, Powers WJ, Videen TO, Price JL, Cryer PE. Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure. Diabetes 2008;57:470-475
13. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
14. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283-1297
15. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, Zagar T, Poole CD. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet 2010;375:481-489
16. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN, DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes 2008;57:995-1001
17. Ryan EA, Shandro T, Green K, Paty BW, Senior PA, Bigam D, Shapiro AM, Vantyghem MC. Assessment of the severity of hypoglycemia and glycemic lability in type 1 diabetic subjects undergoing islet transplantation. Diabetes 2004;53:955-962
18. Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA, STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-320
19. Robertson RP. Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010;59:1285-1291
20. Haymond MW, Schreiner B. Mini-dose glucagon rescue for hypoglycemia in children with type 1 diabetes. Diabetes Care 2001;24:643-645
21. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27
22. Saleh TY, Cryer PE. Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. Diabetes Care 1997;20:1231-1236
23. Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab 2006;91:2087-2092
24. Cooperberg BA, Breckenridge SM, Arbelaez AM, Cryer PE. Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. Diabetes Care 2008;31:2271-2272
25. Battram DS, Graham TE, Richter EA, Dela F. The effect of caffeine on glucose kinetics in humans-influence of adrenaline. J Physiol 2005;569: 347-355
26. Richardson T, Thomas P, Ryder J, Kerr D. Influence of caffeine on frequency of hypoglycemia detected by continuous interstitial glucose monitoring system in patients with long-standing type 1 diabetes. Diabetes Care 2005;28:1316-1320
27. Smith D, Pernet A, Rosenthal JM, Bingham EM, Reid H, Macdonald IA, Amiel SA. The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia. Diabetologia 2004;47:1704-1711
28. Gabriely I, Hawkins M, Vilcu C, Rossetti L, Shamoon H. Fructose amplifies counterregulatory responses to hypoglycemia in humans. Diabetes 2002; 51:893-900
29. McCrimmon RJ, Evans ML, Fan X, McNay EC, Chan O, Ding Y, Zhu W, Gram DX, Sherwin RS. Activation of ATP-sensitive K+ channels in the ventromedial hypothalamus amplifies counterregulatory hormone responses to hypoglycemia in normal and recurrently hypoglycemic rats. Diabetes 2005;54:3169-3174
30. Fan X, Ding Y, Cheng H, Gram DX, Sherwin RS, McCrimmon RJ. Amplified hormonal counterregulatory responses to hypoglycemia in rats after systemic delivery of a SUR-1-selective K+ channel opener? Diabetes 2008;57:3327-3334
31. Raju B, Cryer PE. Loss of the decrement in intraislet insulin plausibly explains loss of the glucagon response to hypoglycemia in insulin-deficient diabetes: documentation of the intraislet insulin hypothesis in humans. Diabetes 2005;54:757-764
32. Tong Q, Ye C, McCrimmon RJ, Dhillon H, Choi B, Kramer MD, Yu J, Yang Z, Christiansen LM, Lee CE, Choi CS, Zigman JM, Shulman GI, Sherwin RS, Elmquist JK, Lowell BB. Synaptic glutamate release by ventromedial hypothalamic neurons is part of the neurocircuitry that prevents hypoglycemia. Cell Metab 2007;5:383-393
33. Pais I, Hubold C, Hallschmid M, Letterer S, Oltmanns K, Schultes B, Born J, Peters A. Blocking NMDA receptor signaling does not decrease hormonal counterregulation to hypoglycemia in humans. Psychoneuroendocrinology 2008;33:1069-1076
34. Klement J, Pais I, Hallschmid M, Hubold C, Knispel A, Oltmanns KM, Schultes B, Born J, Peters A. Blocking AMPA receptor signalling by caroverine infusion does not affect counter-regulation of hypoglycaemia in healthy men. Diabetologia 2009;52:1192-1196
35. Ramanathan RP, Cryer PE. Adrenergic mediation of hypoglycemia-associated autonomic failure. Diabetes. In press
36. Briscoe VJ, Ertl AC, Tate DB, Davis SN. Effects of the selective serotonin reuptake inhibitor fluoxetine on counterregulatory responses to hypoglycemia in individuals with type 1 diabetes. Diabetes 2008;57:3315-3322
37. Sanders NM, Wilkinson CW, Taborsky GJ Jr, Al-Noori S, Daumen W, Zavosh A, Figlewicz DP. The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 2008;294:E853-E860
38. Caprio S, Gerety G, Tamborlane WV, Jones T, Diamond M, Jacob R, Sherwin RS. Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects. Am J Physiol 1991;260: E852-E858
39. Leu J, Cui MH, Shamoon H, Gabriely I. Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade. J Clin Endocrinol Metab 2009;94:3372-3380
40. Gabriely I, Shamoon H. Opioid receptor blockade during antecedent hypoglycemia prevents exacerbation of HAAF in type 1 diabetes mellitus (Abstract). Diabetes 2010;59:A206
41. Poplawski MM, Mastaitis JW, Mobbs CV. Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure. Diabetes 2011; 60:39-46